10 results about "CD33" patented technology

This invention describes CD33 antibodies and their antigen-binding fragments, as well as CD33 / vδ2 multispecific antibodies or their antigen-binding fragments. The invention also describes polynucleotides encoding these antibodies, compositions comprising these antibodies, methods for producing these antibodies, and methods for treating or preventing diseases such as hematological cancers using these antibodies.

CD33 antibodies, and antigen-binding fragments thereof, and CD33 / Vδ2 multispecific antibodies, or antigen-binding fragments thereof, are described. Also described are polynucleotides encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as hematological cancers.

Disclosed herein are monospecific and multispecific antibodies specific for CD28 and CD3E, and one or more of OX-40, CD40, 4-1BB, HSA, IL-22, PD-L1, CD16, CD47, CD33, LAG3, and EGFR.

The process of inducing pre-mRNA splicing was disclosed. CD33 Novel antisense oligonucleotides that skip exon 2 in genes and their potential applications in treating neurodegenerative diseases such as Alzheimer's disease.

This disclosure relates to the use of cells having identifiable surface proteins, which have engineered or naturally occurring mutations but are functional surface proteins, for therapeutic use. The present invention also relates to the use of cells having identifiable CD33 surface protein variants but are functional surface proteins, for therapeutic use, particularly in adoptive cell therapy.

Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion / activation processes utilizing IL-2, IL-7, IL-15, and / or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.

This invention provides CD33-targeting CAR-gdT cells and their application in the treatment of acute myeloid leukemia. Specifically, this invention, through screening, provides CD33-CAR-γδT cells with high transfection efficiency, strong proliferative capacity, and efficient killing of target cells. This invention also provides a method for preparing CD33-CAR-γδT cells and their application in the treatment of acute myeloid leukemia.

CD33 offers a more powerful antagonist. [Solution] A CD33-binding polypeptide and a method for treating, for example, leukemia using the CD33-binding polypeptide are provided. The CD33-binding polypeptide comprises at least one VHH domain.

A suite of novel human anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33 or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).